title: Intravitreal bevacizumab versus posterior subtenon triamcinolone in diffuse diabetic macular edema.
abstract: The aim of the study was to compare intravitreal bevacizumab (IVB) and posterior subtenon triamcinolone (PST) as an adjunct to laser treatment in diffuse diabetic macular edema (Diffuse DME). Prospective-randomized control trial of 30 eyes of 30 diabetic patients having Diffuse DME with maximum retinal thickness (MRT) was more than or equal to 350 µm. The subjects were randomly allocated into two groups. Group A (12 eyes) received IVB and group B received PST (18 patients) before laser treatment. Grid laser treatment was done when the MRT decreased to less than 350 µm. OCT thickness-guided repeat injections were given if required. The patients had minimum follow-up of 6 months. At 6-month follow-up, the two groups were compared for (1) Maximum change in visual acuity letter score using logMAR chart (2) Reduction in MRT on OCT. The mean logMAR visual acuity at baseline was 0.63 ± 0.45 (0-1.6) in group A and was 0.76 ± 0.38 (0.2-1.3) in group B. The mean logMAR visual acuity at 6 month in group A was 0.34 ± 0.21 (0-0.6) and in group B was 0.64 ± 0.37 (0.3-1.3). The mean visual acuity at last follow-up was significantly better in group A than group B (p = 0.02). The mean change in MRT in Group A and Group B was 177.8 ± 85.64 and 156.07 ± 102.86, respectively, which was significantly better than the baseline in both the groups and was comparable in both groups. The study provides evidence to support the use of IVB over PST in diffuse diabetic macular edema.
authors.affiliation: Department of Ophthalmology, Government Medical College Hospital, Chandigarh, India, sshaveta@gmail.com.
authors.forename: Shaveta
authors.initials: S
authors.lastname: Bhayana
authors.forename: Sunandan
authors.initials: S
authors.lastname: Sood
authors.forename: Subina
authors.initials: S
authors.lastname: Narang
authors.forename: Neha Khurana
authors.initials: NK
authors.lastname: Sethi
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D053685:Laser Therapy; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014222:Triamcinolone Acetonide / Q000008:administration & dosage*; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D000068258:Bevacizumab; D014222:Triamcinolone Acetonide
references.citation: Eye (Lond). 2004 Oct;18(10):963-83
references.pmid: 15232600
references.citation: Arch Ophthalmol. 1985 Dec;103(12):1796-806
references.pmid: 2866759
references.citation: Arch Ophthalmol. 2009 Mar;127(3):245-51
references.pmid: 19273785
references.citation: Retina. 2010 Nov-Dec;30(10):1638-45
references.pmid: 20838357
references.citation: Korean J Ophthalmol. 2006 Dec;20(4):205-9
references.pmid: 17302204
references.citation: Am J Ophthalmol. 2004 Dec;138(6):970-7
references.pmid: 15629288
references.citation: Ophthalmology. 1991 Oct;98(10):1594-602
references.pmid: 1961650
references.citation: Ophthalmology. 2007 Jun;114(6):1190-6
references.pmid: 17544778
references.citation: Br J Ophthalmol. 2007 Apr;91(4):449-54
references.pmid: 17077114
references.citation: Retina. 2005 Oct-Nov;25(7):828-34
references.pmid: 16205559
references.citation: Ophthalmology. 2005 Jun;112(6):1086-91
references.pmid: 15885789
references.citation: Retina. 2006 Nov-Dec;26(9):999-1005
references.pmid: 17151486